Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo trial aims to fight advanced bowel cancer

NCT ID NCT05171660

Summary

This study is testing if adding a new immunotherapy drug called sintilimab to standard chemotherapy works better for people with advanced colorectal cancer that has spread and has a specific genetic change (RAS mutation). It will involve about 446 adults who have not yet received treatment for their advanced cancer. The goal is to see if the combination helps control the cancer for longer and improves survival.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER STAGE IV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Xuefeng Fang

    Hangzhou, Zhejiang, 310009, China

Conditions

Explore the condition pages connected to this study.